| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03268278 Details | 2019-04-23 Interventional | 1 | 10 | Anesthetics Anesthetics, Lo… Buprenorphine Epinephrine Lidocaine Pain, Postopera… Postoperative P… | Loss of interest - | |||
| NCT03246399 Details | 2019-04-23 Interventional | 1 | 6 | Lorecivivint Intervertebral … Spinal Diseases Degenerative Di… | Study stopped due to business reasons, following full enrollment of the first dose cohort. - | |||
| NCT02087085 2013-003320-36 Details | 2019-04-23 Interventional | 2 | 310 | Brimonidine Tar… Atrophy Geographic Atro… Macular Degener… | - - | |||
| NCT02595840 2014-001983-36 Details | 2019-04-19 Interventional | 2 | 4 | Afatinib Pemetrexed Carcinoma, Non-… Non-small-cell … | Futility - | |||
| NCT01756924 Details | 2019-04-19 Interventional | 2 | 14 | Anti-Bacterial … Cefazolin Ceftaroline Ceftriaxone Ciprofloxacin Daptomycin Fusidic Acid Levofloxacin Linezolid Nafcillin Oxacillin Rifampin Trimethoprim, S… Vancomycin Arthritis, Infe… Communicable Di… Infections Infected Spacer… Prosthetic Join… Prosthetic Join… | This study has been terminated; alternative study designs are being considered. Fusidic acid
remains available under an Expanded Access Protocol. - | |||
| NCT03490019 Details | 2019-04-18 Interventional | 2 | 0 | Metformin Bardet-Biedl Sy… Laurence-Moon S… Syndrome Vision Disorder… Vision, Low Visual Impairme… | unrealizable wishes of national authorities - | |||
| NCT03386838 2017-003059-46 Details | 2019-04-18 Interventional | 3 | 0 | Carboplatin Cetuximab Fluorouracil Linrodostat Nivolumab Carcinoma, Squa… Squamous Cell C… Head and Neck C… | Business objectives have changed. - | |||
| NCT02995512 Details | 2019-04-18 Interventional | 4 | 0 | Colchicine Infarction Myocardial Infa… | feasibility - | |||
| NCT02809755 Details | 2019-04-18 Interventional | 4 | 0 | Lidocaine Shoulder Pain Obesity | While 33 people signed consent, no one was enrolled in the study, because none of these
patients developed shoulder pain in the recovery room. - | |||
| NCT01942187 Details | 2019-04-18 Interventional | 4 | 0 | Aripiprazole Bupropion Depression Depressive Diso… Depressive Diso… Dysthymic Disor… Depressive Diso… Major Depressiv… | No participants enrolled. - | |||
| NCT01743755 2011-004566-14 Details | 2019-04-18 Interventional | 4 | 413 | Dexamethasone Pneumonia Community-acqui… | - - | |||
| NCT00924950 Details | 2019-04-18 Interventional | 4 | 35 | Betamethasone Calcitriol Psoriasis Plaque Psoriasi… Psoriasis Vulga… | - - | |||
| NCT03153813 Details | 2019-04-17 Interventional | 3 | 22 | Capsaicin Osteoarthritis Osteoarthritis,… Pain | - - | |||
| NCT03076684 Details | 2019-04-17 Interventional | 1 | 0 | Allopurinol Hyperuricemia | Preliminary data collected and diets developed. Funding has ended and data used to support a
larger application to test the hypothesis. - | |||
| NCT02568683 2015-002731-17 Details | 2019-04-17 Interventional | 1/2 | 10 | Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… Non-Hodgkin Lym… | - Because the study was terminated after enrolling only 10 participants, the dose expansion stage and the planned efficacy analyses were not conducted. | |||
| NCT01479465 2011-003754-61 Details | 2019-04-17 Interventional | 2 | 266 | Fluorouracil Irinotecan Leucovorin Adenocarcinoma Colorectal Neop… Colorectal Canc… | - - | |||
| NCT00701233 Details | 2019-04-17 Interventional | 2 | 0 | Botulinum Toxin… Carpal Tunnel S… Syndrome | Unable to generate MD's and patients for this study - | |||
| NCT03419559 Details | 2019-04-16 Interventional | 2 | 0 | Durvalumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | The treatment landscape for NSCLC has evolved in the past year. An additional NSCLC arm will be
added to the IOV-COM-202 study using TIL + pembrolizumab. - | |||
| NCT02738008 2014-004201-33 Details | 2019-04-16 Interventional | 2 | 12 | Entecavir Histamine Antag… Histamine H1 An… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Company decision to discontinue trial The decision to discontinue development of ARC-EXl-containing programs was not due to any safety findings in clinical studies. | |||
| NCT02604212 2014-004751-31 Details | 2019-04-16 Interventional | 2 | 32 | Entecavir Histamine Antag… Histamine H1 An… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Company decision to discontinue trial - |